During the past decade, Charité Campus Mitte conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 9 clinical trials were completed, i.e. on average, 39.1% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 5 clinical trials were completed. i.e. 45.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Charité Campus Mitte" #1 sponsor was "Charite University, Berlin, Germany" with 3 trials, followed by "Pfizer" with 3 trials sponsored, "Abbott Medical Devices" with 2 trials sponsored, "H. Lundbeck A/S" with 2 trials sponsored and "ResMed" with 2 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Charité Campus Mitte" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "Basilea Pharmaceutica" with 1 trials as a collaborator, "Cardiovascular European Research Center (CERC)" with 1 trials as a collaborator and "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Charité Campus Mitte" are "Coronary Artery Disease" (3 trials), "Crohn's Disease" (3 trials), "Atrial Fibrillation" (2 trials), "Emphysema" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "Charité Campus Mitte" in a lesser frequency.

Most popular intervention types in "Charité Campus Mitte" are "Drug" (30 trials), "Device" (8 trials), "Other" (6 trials), "Biological" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Eptinezumab" (2 trials), "Guselkumab" (2 trials), "Rituximab" (2 trials) and "46 hrs Holter ECG recording" (1 trials). Other intervention names were less common.

The vast majority of trials in "Charité Campus Mitte" are 43 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Charité Campus Mitte". undefined are not yet recruiting, 7 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Charité Campus Mitte, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Charité Campus Mitte, 1 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 7 trials that are defined as “Not Applicable".